Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis.
Explore this paper's citation graph
Summary
WDSM represents a rare clinically and molecularly heterogeneous variant of SM that requires unique diagnostic criteria to avoid a misdiagnosis of cutaneous mastocytosis per current World Health Organization criteria.
- Type
- article
- Published
- 2016-01-01
- Cited by
- 77
- References
- 37
- Access
- Open access
- OpenAlex
- https://openalex.org/W26100086
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:23445487
Keywords
Art
References
- Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.
- Well-differentiated systemic mastocytosis: A new disease variant with mature mast cell phenotype and lack of codon 816 c-Kit mutations
- Immunophenotypic characterization of bone marrow mast cells in mastocytosis and other mast cell disorders.
- WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
- Current state of biology and diagnosis of clonal mast cell diseases in adults
- A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy.
- The tryptase positive compact round cell infiltrate of the bone marrow (TROCI-BM): a novel histopathological finding requiring the application of lineage specific markers
- Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients.
- Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit.
- Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype
- Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA)
- Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.
- Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay.
- A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.
- Immunophenotyping in systemic mastocytosis diagnosis: ‘CD25 positive’ alone is more informative than the ‘CD25 and/or CD2’ WHO criterion
- Imatinib for systemic mast-cell disease.
- Resolution of clonal origins for endometriotic lesions using laser capture microdissection and the human androgen receptor (HUMARA) assay.
- Hematologic aspects of mastocytosis: I: Bone marrow pathology in adult and pediatric systemic mast cell disease.
- Evaluation of the WHO criteria for the classification of patients with mastocytosis
- One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes.
Cited by
- Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression
- WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
- Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology.
- Diagnosis and classification of mastocytosis in non‐specialized versus reference centres: a Spanish Network on Mastocytosis (REMA) study on 122 patients
- Mastocytoses systémiques : aspects cytologiques et histologiques en hématologie
- Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature
- Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities
- Advances in the classification and treatment of mastocytosis: current status and outlook toward the future
- Systemic mastocytosis with KIT V560G mutation presenting as recurrent episodes of vascular collapse: response to disodium cromoglycate and disease outcome
- Mast cell activation syndromes.
- Mast Cell Disease Assessment by Flow Cytometric Analysis.
- Cutaneous Mastocytosis in Adults and Children: New Classification and Prognostic Factors.
- New Insights into Clonal Mast Cell Disorders Including Mastocytosis.
- Bone Marrow Expression of Mast Cell Disorders.
- Diffuse cutaneous mastocytosis with novel somatic KIT mutation K509I and association with tuberous sclerosis
- The Mastocytosis Society Survey on Mast Cell Disorders: Part 2-Patient Clinical Experiences and Beyond.
- Cutaneous Mastocytosis With Predominant Infiltration of Promastocytes.
- Bone Marrow Mast Cell Antibody-Targetable Cell Surface Protein Expression Profiles in Systemic Mastocytosis
- Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management.
- The Spectrum of Aggressive Mastocytosis: A Workshop Report and Literature Review
Related papers
No related papers recorded.